EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.

Employees

Sector

Drug Retailers

Calendar

11-05 Earnings release - Q2 2027

More about the company

Quotes

Date	Price	Change	Volume
01/10/26	SEK 22.80	-0.87%	5,498
30/09/26	SEK 23.00	0.00%	13,608
29/09/26	SEK 23.00	0.00%	18,375
28/09/26	SEK 23.00	-1.71%	14,806
25/09/26	SEK 23.40	+1.74%	4,594

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 11:57:46 01/10/2026 +04			5-day change	1st Jan Change
22.80 ^SEK	-0.87%		-0.87%	-60.55%

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW

Market Cap	679M 68.04M 59.91M 56.77M 51.25M 96.59M 6.52B 97.84M 261M 3.34B 255M 250M 10.69B	P/E 2027 *	-	P/E 2028 *	9.62x
Enterprise Value	1.1B 110M 96.7M 91.62M 82.71M 156M 10.53B 158M 422M 5.38B 412M 403M 17.26B	EV / Sales 2027 *	2.25x	EV / Sales 2028 *	1.81x
Free-Float	42.3%	Yield 2027 *	-	Yield 2028 *	-

Markets		Quality
Nasdaq Stockholm	EQL	Delayed
Deutsche Boerse AG	7JK	End-of-day quote
Deutsche Boerse AG	7JK	Delayed
Börse Stuttgart	7JK	Delayed
Boerse Muenchen	7JK	Real-time

08-20	EQL Pharma AB Appoints Niraj Kumar as New Board Member	CI
08-17	EQL Pharma CFO Allan Sylvest Aasberg makes his first share purchase	FW
08-14	DNB Carnegie raises its justified value for EQL Pharma	FW
08-12	EQL Pharma Enters UTI Treatment License Deal in Hungary	MT
08-12	EQL Pharma: Analysguiden cuts fair value estimate to 38 kronor	FW
08-12	EQL Pharma licenses Memprex to partner in Hungary	FW
08-12	EQL Pharma AB Licenses Memprex for Sale in Hungary	CI
08-07	EQL Pharma AB, Q1 2027 Earnings Call, Aug 07, 2026
08-07	EQL Pharma AB Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO (update)	FW
08-07	EQL Pharma swings to an operating loss, 'going through a tough period' - CEO	FW
08-07	Eql Pharma AB Provides Earnings Guidance for the Year 2026/27	CI
07-28	DNB Carnegie cuts justified value for EQL Pharma	FW

EQL Pharma AB Stock

Stocks

EQL

SE0005497732

Drug Retailers

Valuation: EQL Pharma AB

Chart: EQL Pharma AB

Latest news: EQL Pharma AB

Last Transcript: EQL Pharma AB

Analysts' recommendations: EQL Pharma AB

Press Releases: EQL Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: EQL Pharma AB

Latest insider transactions

Other Drug Retailers

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-20	Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026	AQ
08-14	EQL Pharma: Improvement emerging, confirmation needed – Q1 review	AQ
08-12	Memprex© (methenamine hippurate) license signed with partner for Hungary	AQ
08-07	EQL Pharma: Soft start as expected, guidance intact	AQ
08-07	Interim Report April - June 2026	AQ

1 day	-0.87%
1 week	-0.87%
Current month	-0.87%
1 month	-11.63%
3 months	-3.80%
6 months	-59.14%
Current year	-60.55%

1 week	22.5	24
1 month	22.2	28.15
Current year	17.38	67.5
1 year	17.38	68.6
3 years	17.38	98.6
5 years	17.38	98.6
10 years	6.45	98.6

Manager	Title	Age	Since
Axel Schörling CEO	Chief Executive Officer	40	17/08/2022
Allan Sylvest Aasberg DFI	Director of Finance/CFO	51	01/04/2026
Martin Kristofferson COO	Chief Operating Officer	48	17/08/2022

Director	Title	Age	Since
Lars Christer Fedrik Fåhraeus CHM	Chairman	61	17/08/2022
Anders Månsson CHM	Chairman	59	-
Ingrid Linda Marie Neckmar BRD	Director/Board Member	53	01/01/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/08/26	Allan Sylvest Aasberg	Buy	Chief Financial Officer	20,000	0.0677%
27/03/26	Axel Schörling	Sell	Chief Executive Officer	24,066	0.0815%
30/12/25	Magnus Erreth	Buy	Executive/Senior Manager	1,000	0.0034%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EQL PHARMA AB	-0.87%	-0.87%	-65.61%	-14.29%	68.04M
JD HEALTH INTERNATIONAL INC.	-0.11%	+0.06%	-45.86%	-11.33%	14.63B
TSURUHA HOLDINGS INC.	-0.95%	-3.21%	-10.12%	+3.87%	6.1B
RAIA DROGASIL S.A.	+1.27%	-5.79%	+1.72%	-32.16%	6.2B
MATSUKIYOCOCOKARA & CO.	+0.51%	-3.03%	-17.95%	-6.67%	6.1B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	+1.42%	+1.06%	-56.98%	-41.29%	5.9B
YIFENG PHARMACY CHAIN CO., LTD.	+1.30%	+5.52%	-5.44%	-20.24%	4.21B
NAHDI MEDICAL COMPANY	+0.05%	-0.33%	-26.67%	-37.82%	3.15B
COSMOS PHARMACEUTICAL CORPORATION	+0.94%	-3.24%	-27.08%	-17.65%	3.1B
CLICKS GROUP LIMITED	-2.34%	-1.42%	-40.70%	-19.20%	2.98B
Average	+0.13%	-1.70%	-29.47%	-19.68%	5.24B
Weighted average by Cap.	+0.26%	-1.67%	-28.30%	-17.99%

	2027 *	2028 *
Net sales	486M 48.74M 42.92M 40.66M 36.71M 69.19M 4.67B 70.08M 187M 2.39B 183M 179M 7.66B	612M 61.36M 54.03M 51.19M 46.22M 87.11M 5.88B 88.23M 236M 3.01B 230M 225M 9.64B
Net income	-	71M 7.11M 6.26M 5.93M 5.36M 10.1M 682M 10.23M 27.32M 349M 26.71M 26.13M 1.12B
Net Debt	417M 41.77M 36.79M 34.85M 31.47M 59.3M 4.01B 60.07M 160M 2.05B 157M 153M 6.56B	430M 43.08M 37.93M 35.94M 32.45M 61.15M 4.13B 61.94M 165M 2.11B 162M 158M 6.77B